Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel…

MarketQuest.biz has presented updated research report titled Global Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 which presents vital answers and interpretations concerning market growth and developments in the market. The report contains insightful information like market share, market size, and growth rate, as well as several challenges and ingrained threats and limitations that have interrupted normal growth prognosis in global Stem Cell Therapy market. The report analyzes the segment expected to dominate the industry and market.This market report includes quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. The report gives information about the supply and demand situation, the competitive scenario, market opportunities, and the threats faced by key players.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitive Intelligence:

The leading players are covered in the global Stem Cell Therapy market report with product description, business outline, as well as production, future demand, company profile, product portfolio, product/service price, capacity, sales, and cost. So the entire information related to the company concerning the specific product and in-depth information of collaborations and all other essential information is added in the research report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/16395

Report has been segmented into geographical segmentation, key players, key topics industry value and demand analysis and forecast and gives comprehensive investigation.The report provides knowledge of the key product segments and their future by having complete insights of market and by making in-depth analysis of market segments. Report includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of global Stem Cell Therapy market.

All top players actively involved in this industry are as follows: Osiris Therapeutics, Molmed, JCR Pharmaceutical, NuVasive, Anterogen, Chiesi Pharmaceuticals, Medi-post, Pharmicell, Takeda (TiGenix)

The report highlights product types which are as follows:Autologous, Allogeneic

The report highlights top applications which are as follows:Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others

Promising regions & countries mentioned in the global Stem Cell Therapy market report:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Market By Manufacturing Cost Analysis:

The study report includes key raw materials analysis, the price trend of key raw materials, key suppliers of raw materials, market concentration rate of raw materials, the proportion of manufacturing cost structure, and manufacturing process analysis. Moreover, the report evaluates the product pricing, production capacity, demand, supply, as well as the historical performance of the global Stem Cell Therapy market.

ACCESS FULL REPORT: https://www.marketquest.biz/report/16395/global-stem-cell-therapy-market-2020-by-company-type-and-application-forecast-to-2025

Report Offerings:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: sales@marketquest.biz Web: http://www.marketquest.biz

See the rest here:
Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel...

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings – PRNewswire

HOUSTON, Feb. 16, 2021 /PRNewswire/ --Iterion Therapeutics, Inc. ("Iterion"), a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has raised $17 million USD in a Series B financing led by Lumira Ventures, with the participation of existing investors, including Sant Ventures, as well as new investors Venture Investors, GPG Ventures, and Viva BioInnovator.

Iterion plans to utilize the proceeds from this financing to advance the development of its lead clinical candidate, Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor.Tegavivint is currently being investigated in a Phase 1/2a clinical trial in patients with desmoid tumors, which are rare, non-metastasizing sarcomas that overexpress nuclear beta-catenin. Iterion has received Orphan Drug Designation for Tegavivint to treat desmoid tumors, a disease for which there are no FDA approved therapies.

In addition to desmoid tumors, Iterion is preparing to initiate clinical programs in 2021 to investigate Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. These cancers are often characterized by nuclear beta-catenin overexpression, providing potential high-value target expansions for Tegavivint.

"We envision incredible potential therapeutic benefits associated with Tegavivint, and are excited to support the Iterion team in its exploration of multiple clinical development opportunities for this potentially groundbreaking therapeutic," said Benjamin Rovinski, Ph.D., Managing Director at Lumira Ventures. "2021 is expected to be a pivotal year for Iterion as the company anticipates initiating clinical trials in AML, NSCLC and pediatric cancers, all indications in which nuclear beta-catenin signaling plays a role. By pursuing a novel mechanism of action, we believe Tegavivint has the potential to overcome challenges faced by prior drugs targeting this pathway."

Nuclear beta-catenin is a highly-studied oncology target associated with numerous cancer types. Tegavivint is unique among nuclear beta-catenin inhibitors in that it binds to TBL1 (Transducin Beta-like Protein One), a novel downstream target in the Wnt-signaling pathway. As such, Tegavivint enables silencing of Wnt-pathway gene expression without affecting other necessary Wnt/beta-catenin functions in the cell membrane, thus avoiding toxicity issues common to other drugs in this pathway.

"We are grateful to have the confidence of investors, including Lumira Ventures, Sant Ventures and others, that appreciate Tegavivint's potential to treat a host of cancers," said Rahul Aras, Ph.D., CEO of Iterion."Nuclear beta-catenin has historically been considered an 'undruggable' oncology target with prior inhibitors having been plagued by toxicity issues, greatly limiting their therapeutic use. Research suggests that these toxicity concerns can be negated by targeting TBL1, a novel downstream target in the Wnt-signaling pathway necessary for beta-catenin's oncogenic activity. This is precisely Tegavivint's mechanism of action and why we believe the technology holds such substantial promise."

Dr. Aras continued, "With the Series B funding, Iterion has the potential to significantly expand our clinical footprint through completion of our ongoing desmoid tumor study and initiate clinical trials in 2021 to investigate Tegavivint in AML, NSCLC, and certain pediatric cancers."

About Iterion TherapeuticsIterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear beta-catenin, a historically "undruggable" oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing clinical programs in additional cancers where nuclear beta-catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. Iterion is the recipient of an up to $15.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information on Iterion, please visit https://iteriontherapeutics.com or follow the Company on Twitter and Linkedin.

Tiberend Strategic Advisors, Inc.Ingrid Mezo (Media)646-604-5150 [emailprotected]

SOURCE Iterion Therapeutics

See more here:
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PRNewswire

Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market – BioSpace

Humanized Mouse and Rat Model Market: Introduction

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81403

Key Drivers, Restrains, and Opportunities of Global Humanized Mouse and Rat Model Market

Request for Analysis of COVID-19 Impact on Humanized Mouse and Rat Model Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81403

North America to Capture Major Share of Global Humanized Mouse and Rat Model Market

Pre Book Humanized Mouse and Rat Model Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=81403&ltype=S

Read more information here:

https://www.transparencymarketresearch.com/humanized-mouse-and-rat-model-market.html

Key Players Operating in Global Humanized Mouse and Rat Model Market

The global humanized mouse and rat model market is highly consolidated due to the presence of key players. A large number of manufacturers hold a major share in their respective regions. Growth strategies adopted by leading players are likely to drive the global humanized mouse and rat model market. For instance, in February 2020, Taconic Biosciences, a global pioneer in offering drug discovery animal model solutions, announced that its humanized immune system mice models were presently being developed in Europe. Local manufacturing makes it easier for Europe-based drug discovery researchers to access this vital oncology research instrument.

Ask for Discount :

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=81403

Major players operating in the global humanized mouse and rat model market are listed below:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit Bhisey Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read more from the original source:
Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market - BioSpace

Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,…

Apoptosis assays marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.10% in the forecast period of 2020 to 2027 and is expected to reach USD 8.80 billion by 2027.

Apoptosis Assays market research report utilizes the graphs and charts which turns it into more visually appealing. This makes available the best way to the users to understand customer and thus increase their satisfaction by answering the needs and expectations. It also helps to see what factors are influencing the business, where the brand is situated, and get the temperature of the market before a product is launched. Once all the market analysis and studies are done, it is time to present them efficiently, so as to onboard everyone and make the right decisions for the business strategy market research reports are the key partners in the matter.

Download Sample PDF Copy of Report + All Related Graphs @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-apoptosis-assays-market

The major players covered in the apoptosis assays market report areMerck Group, Thermo Fisher Scientific, Inc., BD, Bio-Rad Laboratories, Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG, Biotium, Inc., Creative Bioarray, GE Healthcare, Danaher Corporation, Geno Technology Inc, GeneCopoeia, Inc, Bio-Techne, PerkinElmer, Promega, General Electric and BioTek among other domestic and global players.

Segmentation:Global Apoptosis Assays Market

Apoptosis Assays MarketBy Product

(Assay Kits, Reagents, Microplates, Instruments),

Apoptosis Assays Market By Technology

(Flow Cytometry, Cell Imaging & Analysis Systems, Spectrophotometry, Other Detection Technologies),

Apoptosis Assays Market By End User

(Pharmaceutical and Biotechnology Companies, Hospital and Diagnostic Laboratories, Academic and Research Institutes),

Apoptosis Assays Market By Application

(Drug Discovery & Development, Clinical & Diagnostic Applications, Basic Research, Stem Cell Research),

Apoptosis Assays MarketBy Country

(U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa)

Enquire Here Get customization & check discount for report @:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-apoptosis-assays-market

Global Apoptosis Assays Market Drivers & Restraints:

The increasing cell-based research will help in escalating the growth of the apoptosis assays market.

The increasing incidence and prevalence of chronic and infectious diseases, development of apoptosis-modulating drugs, rising funding for cancer research, growing population suffering from chronic and autoimmune diseases are some of the factors expected to drive the growth of the apoptosis assays market in the forecast period of 2020 to 2027.

On the other hand, the growing adoption of apoptosis assays in developing markets will create several opportunities that will lead to the growth of the apoptosis assays market in the above mentioned period.

Lack of skilled personnel for research and development of apoptosis assays will likely to hamper growth of the apoptosis assays market in the above mentioned period.

Table of Contents:

Know More About Apoptosis assays market @https://www.databridgemarketresearch.com/reports/global-apoptosis-assays-market

Key points for analysis

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email:Corporatesales@databridgemarketresearch.com

Follow this link:
Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,...

Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer…

Written by AZoMFeb 16 2021

Dublin, Ireland, 16 February 2021 Tibidabo Scientific Industries Ltd (Tibidabo Scientific), a global leader and supplier of highly differentiated technology for scientific research, aerospace, and industrial markets, has today announced the appointment of John LaViola as its Chief Technology Officer (CTO) and Head of Business Development.

John LaViola

We are honored to welcome John to our team. As a visionary executive, his technology leadership, scientific rigor, and unique insights are well-known throughout the scientific imaging community. Johns appointment comes at an exciting time for our company, as we accelerate technological innovation and expansion of our growing product offering, explained Paul Murtagh, Chairman & Chief Executive Officer at Tibidabo Scientific. In organizations ranging in size and complexity from early stage to global enterprises, John has been managing R&D and Business Development of medical device, scientific, and imaging systems for over 35 years across a broad range of clinical and scientific disciplines. We are looking forward to harnessing his unique skillset across our expanding business.

Mr. LaViola will lead the companys technology vision and strategy, define the future direction of R&D, and oversee our Mergers & Acquisitions execution and integration. Since 2014, John has served as Vice President, Business Development, and in 2018 assumed leadership for Strategic Innovation in Hologic, Inc.s (Nasdaq: HOLX) Breast and Skeletal Health Solutions division. At Hologic, John was responsible for mergers and acquisitions, technology partnerships, and business alliances, as well as product and service innovation strategy in Hologics largest business unit. He led numerous public and private acquisitions, as well as consummated several strategic partnerships. With a lengthy track record of developing and commercializing disruptive innovations, John previously held technology leadership roles as Vice President, R&D from 2008, and as Senior Director, R&D from 2002 at Hologic.

To learn more, please visit http://www.tibidaboscientific.com

Tibidabo Scientific Industries is a global leader and supplier of highly differentiated technology for scientific research, aerospace, and industrial markets. We succeed by helping customers push boundaries in radiobiology, stem cell research, high-performance imaging, radiation detection, surveillance, space exploration and advanced scintillators. With our roots dating back to H2S phosphor screens in radar critical to the Allied defense during World War II, the impact of our products is now felt from the deepest recesses of the earth, to cutting-edge cancer research, and to the far reaches of space. Our collaborative approach and expanding global team enable our customers to make smarter decisions and adopt more effective solutions with ground-breaking technologies. Our philosophy, culture and strategy are guided by the Tibidabo Business Matrix (TBM), a customer, quality, performance and people-oriented management approach with a system of continuous improvement at its core. For further information, please contact Diane Brau, Corporate Communications [emailprotected]

More:
Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer...

How Irish medtech came to thrive – Med-Tech Innovation

Dr Paul Anglim, partnership development lead for EIT Health Ireland-UK, takes a look at how Irelands thriving medtech ecosystem came to be, and why it continues to go from strength to strength.

In understanding Irelands success in medtech, its important to look at how Ireland turned around its manufacturing slump to become a hotspot for nine of the worlds top ten medtech companies.

The origins of its prosperous medtech sector can be traced back to its highly-skilled manufacturing workforce and strategic government support. When the manufacturing industry suffered a downturn in the 1980s, both the Irish government and those running the sites wanted to safeguard and grow the field of manufacturing.

For them, it was time to embed R&D and innovation into medtech.

Making Ireland an attractive place for R&D

Over the next few decades, the Irish governments strategy went beyond offering physical space and taxation grants, with the development of strategic funding agencies and initiatives.

In 2015, the Science Foundation Irelands CRAM Centre for Research in Medical Devices launched Irelands first stem cell manufacturing centre at NUI Galway. With the goal of positioning Ireland as the leader in medical device technology development, the SFI CRAM focusses on delivering affordable transformative solutions for chronic diseases.

Other collaborations between the government, health services and leading universities have further cemented R&D in industry and Irelands healthcare system. Take, for example, the establishment of the Health Innovation Hub Ireland (HIHI) at University College Cork in 2016.

Backed by Enterprise Ireland and the Health Service Executive, the HIHI incorporatespartnering institutes Trinity College Dublin, NUI Galway, Cork Institute of Technology (CIT) andassociated hospital groups to lead on ground-breaking research and harness new healthcare technology, services and products.

The development of clinical and patient-focussed research has paved the way for Ireland to lead on the exchange of technology ideas. According to IDA Ireland,government grant assistance is responsible for 70% of medtech companies in Ireland engaging in research and development activities.

The goal to entrench R&D in the medtech sector is fast becoming a reality.

Industry and government alignment

As the medtech industry looks drive its growth, alignment between governmental agencies and key associations have played a major role in making this possible.

The IDA has made Ireland an attractive place to do business. The break-up of the IDA into three separate organisations in the mid-1990s enabled it to focus on driving high-quality foreign direct investment in Ireland. The US-based medtech company Strykers 2019 investment of more than 200 million in R&D at its Cork facilities is just one example of the IDAs success in brokering landmark deals.

Underscoring its support of industry, the IDA recently announced that it is set to deliver a targeted COVID-19 fund, investing a total of 200 million in medical technologies and pharmaceuticals.

In addition to the IDA, the Irish Medtech Association has been vital in championing the needs of multinationals corporations and SME member companies to the Irish government. Sitting within Ibec, the Irish Medtech Association has a clear grasp on what the actual needs of industry are, how to represent them to governmental bodies and how to ensure Ireland remains a key location for companies to base their operations.

A burgeoning entrepreneurial mindset

There has also been shift in perception on what is means to be an entrepreneur. People want people to be successful. The entrepreneurial mindset is common among university students of today and theres an abundance of university-led programmes to develop innovative ideas.

NUI Galways BioInnovate Fellowship programme has paved the way for a plethora of successful medtech start-ups. Supported by Enterprise Ireland, BioInnovate delivers needs led innovation based on a proven Stanford BioDesign framework, identifying where recommended solutions would have the most impact.

BioInnovate, like other university-led fellowships, is physically housed in the same place as earlier stage programmes, enabling innovators to meet, network and share new ideas.

In these spaces, the entrepreneurial mindset is the norm, and new innovators emerge in Irelands medtech sector.

Ireland as a thriving medtech ecosystem

Taking into account the support from government agencies, industry, clinical and academic institutions, the existence of Irelands 300-plus community of medtech companies can be better understood.

It is in this dynamic environment that EU-backed organisations like EIT Health, a network of leading health innovators, have decided to expand their presence in Ireland.

Read more:
How Irish medtech came to thrive - Med-Tech Innovation

Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,…

According to the new market research report of Index Markets Research, theCell Expansion Market by Product Type(Human cells, Animal cells),by Application (Regenerative Medicine and Stem Cell Research, Cancer and Cell-based Research, Others) and by Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) Global Forecast to 2026. The worldwide Cell Expansion Market size in 2021 is assessed at USD XX.XX billion and is projected to arrive at USD XX.XX billion by 2026, at a CAGR of X.X% from 2021 to 2026.[Get a Free Sample PDF Report to Understand our Report Before You Purchase]The report helps in evaluating the current situation of the worldwide Cell Expansion market scene and henceforth supporting the customers in settling on educated choices identified with their business systems and speculations. The report likewise subtleties a solid appraisal of the effect of the COVID-19 pandemic on the Cell Expansion market and has a record of systems and strategies embraced by significant parts in the Cell Expansion market to guarantee most extreme profitability and productivity.

What does the Report Include?

The market report incorporatessubjective and quantitative analysisof a few factors, for example, thekey driversand restrictions that will affect development. Furthermore, the report gives bits of knowledge into theterritorial analysisthat covers various areas, adding to the development of the market. It incorporates thecompetitive landscapethat includes the main organizations and the reception of procedures to declare associations, present new products, and team up to additionally add to the development of the market somewhere in the range of 2021 and 2026. In addition, the analysis investigator has embraced a few explorationstrategies to separate data about the latest thingsand industry improvements that will drive the market development during the forecast period.

Key benefits for stakeholders

Porters five powers investigation helps the capability of the purchasers and providers and the serious situation of the industry for strategy building. It diagrams the latest things and future estimations of the market from 2021 to 2026 to comprehend the predominant chances and potential venture pockets. The significant nations in the area have been planned by their individual income commitment to the regional market. The key drivers, restrictions, and opportunities and their definite effect analysis are clarified in the investigation. The profiles of vital participants alongside their key vital advancements are enrolled in the report.

Browse Detailed Research report @https://www.indexmarketsresearch.com/report/global-cell-expansion-market-8/471256/

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments:The investigation additionally incorporates the key advancements of the market, involving R&D, new product dispatch, M&A, arrangements, coordinated efforts, organizations, joint endeavors, and provincial development of the main rivals working in the market on a worldwide and local scale.

Analytical Tools:The Cell Expansion Market Report incorporates the precisely contemplated and surveyed information of the key business players and their extension in the market by methods for various insightful instruments. The logical devices, for example, Porters five powers investigation, SWOT examination, plausibility study, and speculation return examination have been utilized to dissect the development of the central participants working on the lookout.

Key Market Features:The report assessed key market highlights, including income, value, limit, limit usage rate, net, creation, creation rate, utilization, import/trade, supply/request, cost, piece of the pie, CAGR, and gross edge. Also, the investigation offers an extensive investigation of the key market elements and their most recent patterns, alongside appropriate market portions and sub-fragments.

Detailed Table of Content:

1. Introduction Research Scope Market Segmentation Research Methodology Definitions and Assumptions 2. Executive Summary 3. Market Dynamics Market Drivers Market Restraints Market Opportunities 4. Key Insights Key Emerging Trends: For Major Countries Key Developments: Capacity Expansions, Acquisitions, Partnerships, etc. Latest Technological Advancement Insights on Regulatory Scenario Porters Five Forces Analysis 5. Qualitative Insights on Impact of COVID-19 on Global Cell Expansion Market Supply Chain Analysis & Challenges due to Covid-19 Steps taken by Government / Companies to Overcome this Impact Potential Challenges and Opportunities due to COVID-19 Outbreak 6. Global Cell Expansion Market Analysis, Insights and Forecast, 2016-2027 Key Findings / Summary Market Size Estimates and Forecast -By Product (Value and Volume) -By Application (Value and Volume) -By Region (Value and Volume) North America Europe Asia Pacific Latin America Middle East & Africa

TOC Continued!https://www.indexmarketsresearch.com/report/global-cell-expansion-market-8/471256/#toc

Why us?

We encourage you with a urgent detailed knowledge report on the Cell Expansion market. We structure the reports to build your work process effectiveness. Descriptive graphs, logical outlines, and more scientific instruments to give the customers more authentic information in successful yet easy to grasp illustrations. We give you a report that teaches you on the difficulties and issues of the Cell Expansion market and gives you information expected to beat those issues and expand your development potential.

Contact Us On: Phone:+1-202-888-3519 Email:sales@indexmarketsresearch.com Web:www.indexmarketsresearch.com

Link:
Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,...

Translational Regenerative Medicine Market: Immunotherapy is projected to be the fastest growing segment during the forecast period – BioSpace

Regenerative medicine is a segment of translational research in molecular biology and tissue engineering. It involves the process of regeneration of human cells, tissues, or organs to re-establish their normal functions through stimulation of bodys repair system. They are widely used in the treatment of many degenerative disorders occurring in the areas of dermatology, orthopedic, cardiovascular and neurodegenerative diseases. Stem cell therapy is the available tool in the field of translational regenerative medicine. It has gained importance in the past few years as it is a bio-based alternative to synthetic options. Stem cells have high power of regeneration. Hence, these enable production of other cells in the body. This has increased demand for stem cell therapy in the treatment of degenerative diseases. Currently, stem cell therapy has applications in the treatment of diseases such as autism, cancer, retinal diseases, heart failure, diabetes, rheumatoid arthritis, Alzheimers. Extensive research is being carried out on stem cell therapy. The Centre for Commercialization of Regenerative Medicine (CCRM) has reported around 1900 active clinical trials undergoing currently. It also reported 574 active industry-sponsored cell therapy clinical studies, 50 of these are in phase 3 development. Hence, stem cell therapy is projected to contribute to the growth of the translational regenerative medicine market. However, ethical issues in the use of embryonic stem cells is likely to restrain the market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30440

Rising prevalence of degenerative diseases, aging population, rapid growth of emerging countries, and technical advancements in developed countries are the major factors fueling the growth of the translational regenerative medicine market.

The global translational regenerative medicine market has been segmented based on product type, therapy, application, and region. In terms of product type, the market has been categorized into cellular and acellular. The cellular segment dominated the global market in 2016. Based on therapy, the global translational regenerative market has been segmented into cell therapy, gene therapy, immunotherapy, and tissue engineering. Immunotherapy is projected to be the fastest growing segment during the forecast period. In terms of application, the market has been segmented into orthopedic & musculoskeletal, cardiology, diabetes, central nervous system diseases, dermatology, and others. Cardiology and orthopedic & musculoskeletal are anticipated to be the fastest growing segments of the global translational regenerative medicine market. In terms of region, the global translational regenerative medicine market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global regenerative medicine market owing to a large number of leading companies and expansion of research and development activities in the U.S. Increased medical reimbursement and advanced health care also drive the market in the region. Orthopedic is the leading application segment contributing to the growth of the market in the region. Asia Pacific is forecasted the huge growth because of large consumer pool, rising income, and health care expenditure. However, the market in Asia Pacific could face challenges such as high cost of bio-based medicines and stringent regulatory policies.

Request for Analysis of COVID-19 Impact on Translational Regenerative Medicine Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=30440

The global translational regenerative medicine market is dominated by key players such as CONMED Corporation, Arthrex, Inc., Organogenesis, Inc., Nuvasive, Inc., Osiris Therapeutics, Inc., Celgene Corporation, Brainstorm Cell Therapeutics Inc. and Medtronic.

Pre Book Translational Regenerative Medicine Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=30440&ltype=S

The following regional segments are covered comprehensively:

Read more information here:

https://www.transparencymarketresearch.com/translational-regenerative-medicine-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit Bhisey Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read this article:
Translational Regenerative Medicine Market: Immunotherapy is projected to be the fastest growing segment during the forecast period - BioSpace

Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First Off-the-shelf Genomic Medicines – Business Wire

BOSTON--(BUSINESS WIRE)--Ensoma, a company expanding the curative power of genomic medicine by pioneering a next-generation in vivo approach, today launched with a $70 million Series A financing led by co-founder and seed investor 5AM Ventures, with participation from F-Prime Capital, Takeda Ventures, Viking Global Investors, Cormorant Asset Management, RIT Capital Partners, Symbiosis II, LLC, and Alexandria Venture Investments. In addition to an equity investment of $10 million in the Series A financing, Takeda Pharmaceutical Company Limited (Takeda) and Ensoma have entered into a strategic collaboration with the potential for upfront and preclinical research payments totaling $100 million as part of a strategic collaboration worth up to $1.25 billion, announced in a separate press release this morning.

The foundation of the companys platform its Engenious vectors is based on over two decades of academic and clinical research generated by scientific co-founders and renowned experts, Hans-Peter Kiem, M.D., Ph.D., of Fred Hutchinson Cancer Research Center, and Andr Lieber, M.D., Ph.D., of University of Washington School of Medicine. The company will be led by biotechnology industry veterans with demonstrated track records in innovative therapeutic modalities, including gene therapy and editing, across an array of disease areas, including rare disease, hematology and oncology.

Ensomas Engenious vectors are designed to deliver a diverse range of genome modification technologies including those that require a high level of packaging capacity directly to hematopoietic stem cells (HSCs) or the various cell types that arise from these cells, such as T cells, B cells and myeloid cells. The companys vectors are optimized to work without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensomas therapies will be designed to be delivered via single injection in diverse environments, including outpatient and areas where access to sophisticated healthcare systems may be limited.

With the launch of Ensoma, we aspire to bring innovative new treatments to patients in a way that is accessible for all, said Paula Soteropoulos, executive chairman of Ensoma. Because our in vivo therapies do not require prior conditioning or stem cell donors, we hope to deliver them as off-the-shelf treatments to address diseases both rare and common dramatically simplifying the logistics of scaling production and reducing patient and healthcare-system burden. Every person, no matter where they are in the world, should have access to the innovative technologies that are changing the way we treat disease.

Engenious Vectors

Ensomas Engenious vectors are specially engineered adenovirus vectors devoid of any viral genome and minimal pre-existing immunity, thus minimizing the chance of an immune response and freeing up ample storage space up to 35 kilobases (kb) of DNA packaging capacity to deliver a diverse range of genome modification technologies. Also known as therapeutic cargo, these technologies may include, separately and in combination, the following:

These approaches enable Engenious vectors to engineer various erythroid, lymphoid (e.g., T cells, B cells) and myeloid (e.g., macrophages, microglia) cell types, with great precision and vast therapeutic potential. Addressable indications range from rare monogenic diseases to broader diseases such as oncology, autoimmunity and infectious diseases via precision, off-the-shelf engineering of the immune system.

Given the highly specific nature of these technologies, Ensomas Engenious vectors enable preferential targeting of HSCs inside the body. Additionally, Ensomas founders have developed an in vivo selection system that can increase the population of genetically modified HSCs, if needed. This proprietary approach enables precise titration to lasting therapeutic levels without the need to re-dose patients, bypassing the immunogenic challenges associated with re-dosing for some other gene therapy modalities.

Ensomas Engenious platform has been extensively validated in numerous preclinical models with a range of genome editing technologies, demonstrating robust genetic modification of bone marrow HSCs and stable long-term expression of therapeutic proteins in small and large preclinical models.

There have been tremendous advancements in technologies to precisely target, genetically edit and modify human disease. However, many of these tools pose delivery challenges; some lack the ability to reach the right cells within the body, while others lack the ability to broadly reach significant numbers of patients due to complex procedures and supply chain challenges, said Kush M. Parmar, M.D., Ph.D., founding chief executive officer of Ensoma. Ensomas scientific approach allows us to do what hasnt been done beforeto make the curative power of genomic medicine and stem cell technology portable so they may be administered in low-resource and outpatient settings for the very first time.

Leadership & Scientific Founders

Ensoma was founded by and incubated within the 4:59 Initiative, the company creation engine of 5AM Ventures. The companys scientific co-founders include Dr. Hans-Peter Kiem, an oncologist and world-renowned pioneer in gene-editing technologies, including stem cell and gene therapies, from Fred Hutch, who also serves as vice president of the American Society of Gene & Cell Therapy and chief scientific and clinical advisor for Ensoma; and Dr. Andr Lieber, an accomplished academic researcher and professor of medicine, Division of Medical Genetics, UW School of Medicine, who has studied the biological and translational aspects of human adenoviruses for more than two decades. Ensoma is based on an exclusively licensed portfolio of technologies developed by the Fred Hutch lab of Dr. Kiem and the University of Washington lab of Dr. Lieber that enable in vivo genome engineering and gene therapy advances of HSCs for therapeutic use in blood diseases.

Following more than 20 years of academic and clinical research, Ensoma has assembled an exceptional team to boldly forge a new era of genomic medicine in vivo, said Bihua Chen, founder and portfolio manager at Cormorant Asset Management. The company is moving swiftly to accelerate and broaden the therapeutic potential of its approach, and I am confident they have the right team and the right technology to potentially bring life-changing, curative therapies within reach for people all over the world.

Additional details surrounding company leadership, including its board of directors, are as follows:

Ensoma has also named its scientific advisory board, which may be viewed here.

About 5AM Ventures

Founded in 2002, 5AM actively invests in next-generation biotech companies. With approximately $1.5 billion raised since inception, 5AM has invested in 89 companies. For more information, please visit http://www.5amventures.com.

About the 4:59 Initiative

The 4:59 Initiative is the internal company creation engine at 5AM Ventures that helps discover, incubate, and fund breakthrough science. The 4:59 team provides hands-on scientific, strategic, and operational support, working closely with academics and entrepreneurs to advance breakthrough science and establish proof-of-concept data to enable a clear path to transformative therapies for patients.

Read the original post:
Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First Off-the-shelf Genomic Medicines - Business Wire

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies – PRNewswire

VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ --Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch's portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company's proprietary Engineered Thymic Niche (ETN) platform. The financing will also enable Notch to expand its team to support the company's future growth, including establishing operations in Seattle, in addition to the company's existing operations in Vancouver and Toronto.

"We are gratified to have the confidence of this exceptional group of investors and have them share in our vision that our platform can be game-changing for cell therapies by easing cell manufacturing and broadening their clinical and commercial potential," said David Main, President and Chief Executive Officer of Notch. "The level of interest in this financing round enabled us to far exceed our original capital-raising goals. With this support, Notch is well positioned to support our partners and advance development of our initial cell therapy products for patients with cancer."

Notch is applying its scalable Engineered Thymic Niche (ETN) technology platform to develop homogeneous and universally compatible, stem cell-derived cell therapies. To date, Notch has assembled a world-class scientific team and built a fully integrated, tightly controlled platform for generating and editing immune cells from clonal stem cells to enable development of a broad range of T cell therapeutics. Notch has an existing partnership with Allogene Therapeutics to apply Notch's proprietary ETN platform to develop CAR-targeted, iPSC-derived, off-the-shelf T cell or natural killer (NK) cell therapies for hematologic cancer indications.

"We have great confidence in Notch's high-caliber management team and the rigorous science underlying its research programs," said David Chang, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene and a member of the Notch Board of Directors. "We are impressed by the company's innovation and accomplishments and pleased to continue our support of Notch as the company advances the development of a new generation of cell therapies for cancer and other immune disorders."

About Notch Therapeutics (www.notchtx.com) Notch is developing a pipeline of cellular immunotherapies originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems. The company has unlocked the ability for large-quantity production of T cells and other cells from any source of stem cells to bring best-in-class cell therapies for cancer and other immune disorders to thousands of patients. The core of the Notch platform is the Engineered Thymic Niche (ETN), which enables precision control of cell fate during the differentiation and expansion of stem cells in suspension bioreactors without the need for feeder cells or serum. The ETN has the potential to generate immunotherapies with decreased variability, increased potency, and engineered improvements. The technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM), which initially incubated the company.

Contact:Mary Moynihan M2Friend Biocommunications 802-951-9600 [emailprotected]

SOURCE Notch Therapeutics

Notch Therapeutics

Here is the original post:
Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies - PRNewswire